Eli Lilly said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana, to expand the supply of its highly popular weight loss drug Zepbound, diabetes treatment Mounjaro ...
Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...
Eli Lilly has some incredibly popular treatments in Mounjaro (diabetes) and Zepbound (weight loss). Demand has been exceeding the available supply by a wide margin. That has been the case with other ...
Eli Lilly & Co. will spend $5.3 billion to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages. The ...
Governor Roy Coope, Eli Lilly officials and others were on hand as the new $2 billion facility opened on Concord Friday, June ...
Eli Lilly & Company has announced it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana, to boost manufacturing of its highly popular weight loss drug Zepbound, diabetes ...
The expansion will enhance Lilly's capacity to manufacture tirzepatide, an active pharmaceutical ingredient for Zepbound and Mounjaro. Eli Lilly expects to begin making medicines in Lebanon ...
(Reuters) -Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana manufacturing plant, more than doubling its previous investment, as it scrambles to meet ...
Eli Lilly announced a partnership with ChatGPT maker OpenAI to use artificial intelligence to develop new treatments for drug-resistant diseases. Novo Nordisk (NVO) plans to invest $4.1 billion in ...
Tirzepatide sales are off the charts but could be much higher if not for supply constraints. Eli Lilly will invest $9 billion in a manufacturing facility to keep up with demand for its weight ...
Novo Nordisk announces a plan to invest $4.1 billion to expand its capacity of making weight loss drug Wegovy and diabetes ...